Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313741 | 0.83 | GRIN2D (0.52) | KDM4ECA12PARP1CA9ALDH1A1 | |
| SCHEMBL16110565 | 0.75 | PARP1 (0.48) | KDM4ECA12PARP1CA9ALDH1A1 | |
| SCHEMBL38236 | 0.75 | KDM4E (0.48) | KDM4ECA12PARP1CA9PDE3B | |
| SCHEMBL37951 | 0.70 | KDM4E (0.67) | KDM4ECA12PARP1CA9PDE3B | |
| SCHEMBL4558727 | 0.70 | KDM4E (0.67) | KDM4ECA12PARP1CA9PDE3B | |
| SCHEMBL29367508 | 0.70 | KDM4E (0.67) | KDM4ECA12PARP1CA9PDE3B | |
| SCHEMBL15009544 | 0.68 | ALDH1A1 (0.61) | KDM4ECA12PARP1CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30275219 | 0.68 | KDM4E (0.63) | KDM4ECA12PARP1CA9PDE3B | |
| Hydrochloric Acid SCHEMBL30832797 | 0.68 | KDM4E (0.63) | KDM4ECA12PARP1CA9PDE3B | |
| Hydrochloric Acid SCHEMBL4647780 | 0.68 | KDM4E (0.63) | KDM4ECA12PARP1CA9PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | claimed |
| WO-2016003296-A1 | (QUINOLINE OR ISOQUINOLINE)SULFONAMIDES OF CYCLIC AMINES AS ANTIPSYCHOTIC DRUGS | INSTYTUT FARMAKOLOGII POLSKIEJ AKADEMII NAUK (PL) | 2016-01-07 | — | — | WO | claimed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | claimed |
| EP-2501236-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-26 | — | — | EP | claimed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | claimed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| EP-0007605-B1 | A PROCESS FOR INVERTING THE CONFIGURATION IN OPTICALLY ACTIVE COMPOUNDS AND OPTICALLY ACTIVE INTERMEDIATE COMPOUNDS AND THEIR SALTS REQUIRED THEREFOR | CIBA-GEIGY AG (CH) | 1982-09-15 | — | — | EP | claimed |
| US-4294966-A | SALT FORMATION | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | claimed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | claimed |
| CN-108026067-B | 6-amino-quinoline-3-carbonitriles as COT modulators | 吉利德科学公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3319955-B1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10703762-B2 | Compound, material for organic electroluminescence device, organic electroluminescence device and electronic apparatus | IDEMITSU KOSAN CO., LTD. (JP) | 2020-07-07 | — | — | US | disclosed |
| US-20190194219-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS EQUIPPED WITH SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2019-06-27 | — | — | US | disclosed |
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-4497813-A | ANTIARRHYTHMIA AGENTS, HYPOTENSIVE AGENTS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1985-02-05 | — | — | US | disclosed |
| EP-0015505-B1 | 3-AMINO-1,2-PROPANE DIOLS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF | CIBA-GEIGY AG (CH) | 1984-08-08 | — | — | EP | disclosed |
| US-4391980-A | FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0007605-B1 | A PROCESS FOR INVERTING THE CONFIGURATION IN OPTICALLY ACTIVE COMPOUNDS AND OPTICALLY ACTIVE INTERMEDIATE COMPOUNDS AND THEIR SALTS REQUIRED THEREFOR | CIBA-GEIGY AG (CH) | 1982-09-15 | — | — | EP | disclosed |
| US-4294966-A | SALT FORMATION | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| EP-0007605-A1 | A process for inverting the configuration in optically active compounds and optically active intermediate compounds and their salts required therefor | CIBA-GEIGY AG (CH) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | KDM4E 1288/4885CA12 259/4885PARP1 1381/4885 |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | KDM4E 3637/4885CA12 2004/4885PARP1 2220/4885 |
| US-20190194219-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS EQUIPPED WITH SAME | OR10J3, EML4, AOC2 | KDM4E 2872/4885CA12 1515/4885PARP1 2976/4885 |
| US-10703762-B2 | Compound, material for organic electroluminescence device, organic electroluminescence device and electronic apparatus | PIEZO1, OR10J3, EPCAM | KDM4E 3529/4885CA12 2495/4885PARP1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.